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Objectives: Bacteriophage-encoded endolysins are a group of enzymes that act
by digesting the peptidoglycan of bacterial cell walls. LysK has been reported to
lyse live staphylococcal cultures. LysK proteins containing only the cysteine/
histidine-dependent amidohydrolase/peptidase (CHAP) domain has the capa-
bility to show lytic activity against live clinical staphylococcal isolates, including
methicillin-resistant Staphylococcus aureus (MRSA). The aim of this study was to
clone and express LysK-CHAP domain in Escherichia coli BL21 (DE3) using pET22b
as a secretion vector. The pET22b plasmid was used, which encoded a pelB
secretion signal under the control of the strong bacteriophage T7 promoter.
Methods: The E. coli cloning strains DH5a and BL21 (DE3) were grown at 37C
with aeration in the Luria-Bertani medium. A plasmid encoding LysK-CHAP in a
pET22b backbone was constructed. The pET22b vector containing LysK-CHAP
sequences were digested with NcoI and HindIII restriction enzymes. Cloning ac-
curacy was confirmed by electrophoresis. The pET22b-LysK plasmid was used to
transform the E. coli strain BL21. Isopropyl b-D-1-thiogalactopyranoside (IPTG)
was added to a final concentration of 1mM to induce T7 RNA polymerase-based
expression. Finally, western blot confirmed the expression of target protein.
Results: In this study, after double digestion of pEX and pET22b vectors with
HindIII and NcoI, LysK gene was cloned into two HindIII and NcoI sites in pET22b
vector, and then transformed to E. coli DH5a. Cloning was confirmed with double
digestion and analyzed with agarose gel. The recombinant pET22b-LysK plasmid
was transformed to E. coli BL21 and the expression was induced by IPTG. The
expression was confirmed by Sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) and western blotting method. Observation of a 28.5 kDa
band confirmed LysK protein expression.
Conclusion: In the present study, LysK-CHAP domain was successfully cloned and
expressed at the pET22b vector and E. coli BL21 (DE3).uted under the terms of the Creative Commons Attribution-NonCommercial-No Derivative
.org/licenses/by-nc-nd/4.0) which permits non-commercial use, distribution, and repro-
ginal author and source are credited.
ase Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
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Lysins are phage-encoded peptidoglycan hydrolases,
which, when applied exogenously as purified recombi-
nant proteins to Gram-positive bacteria, bring about
rapid lysis and death of the bacterial cell [1,2]. Unlike
antibiotics, phage lysins can be used to selectively target
specific pathogenic bacteria without affecting the sur-
rounding commensal microflora. They are reported to
have a narrow host range similar to that of their phage
producers, rendering them generally either species [3,4]
or genus specific [5,6]. The potential of these enzymes
as novel therapeutics against a number of Gram-positive
pathogens on mucosal surfaces and in systemic in-
fections has previously been demonstrated [7e16]. In
relation to bacterial resistance, no strains have yet been
identified with resistance to phage lysins [1,3,14]. It has
been suggested that these enzymes have evolved to
target specific molecules in the host peptidoglycan that
are essential for cell viability, making resistance an
unlikely event [17,18]. In general, Staphylococcus
aureus phage lysins display a multidomain modular
structure comprising a C-terminal cell wall binding
domain and two N-terminal catalytic domains. Exam-
ples include LysK, MV-L, phi11, and LysH5 [15,19,20].
Native lysins of S. aureus, with the exception of MV-L,
have typically shown poor expression, insolubility, and
low activity when generated as recombinant proteins in
a heterologous host [21e23].
However, a number of lysins have been reported,
which consists of two catalytic domains including those
of S. aureus (LysK, Phi11, and MV-L), where endo-
peptidase activity is a common feature [5,15,24]. Of all
lysins reported to date, the streptococcal phage lysin
PlyC is particularly unique, as it displays a multimeric
modular structure consisting of two distinct gene prod-
ucts designated PlyCA (50 kDa heavy chain) and PlyCB
(8 kDa light chain) [25]. The C-terminal binding domain
of the majority of lysins is responsible for attaching the
enzyme to its specific substrate in the bacterial cell wall
via noncovalent binding of carbohydrate ligands [26]. A
recent study on the crystal structure of the pneumo-
coccal phage lysin Cpl-1 in free and choline-bound
states suggested that the choline-binding domain as-
sists in the correct positioning of the N-terminal cata-
lytic domain [27]. Although it appears that the C-
terminal domain is necessary for lytic activity of some
endolysins [14,23,26], this is not always the case. A
number of enzymes have shown an increased lytic ac-
tivity upon removal of the binding domain [28e30].
For example, when LysK was truncated to its N-terminal
endopeptidase domain, cysteine/histidine-dependent
amidohydrolase/peptidase (CHAP), it had a two-fold
higher lytic activity than the native enzyme [30]. It is
possible that the C-terminal binding domain in the
native enzyme may be limiting the potential activity ofthe N-terminal lytic domain by only allowing it to
configure and function when bound to its target in the
cell wall [30,31]. In contrast to lysins against Gram-
positive pathogens, the enzymes associated with
Gram-negative phages are often globular single-module
enzymes as in the T7 lysin (lysozyme) [32,33]. LysK
has been reported to lyse live staphylococcal cultures.
LysK proteins containing only the CHAP domain has
the capability to show lytic activity against live clinical
staphylococcal isolates, including methicillin-resistant
S. aureus (MRSA). The aim of this study is to clone
and express LysK-CHAP domain in Escherichia coli
BL21 (DE3) using pET22b. In the current research, we
used pET22b because particular interest for the
expression of disulfide bonded proteins is a family of
pET vectors containing the N-terminal pelB secretion
signal, which directs synthesized polypeptides to the E.
coli periplasm [34]. Disulfide oxidoreductases and
isomerases located in the E. coli periplasm catalyze the
formation of disulfide bonds, enabling the accumulation
of properly folded soluble protein and making the
periplasm an ideal compartment for expression of
certain therapeutic proteins. [35]. Construction of a
single-domain protein for therapeutic purposes is desir-
able as well as facilitating protein production; this may
decrease the probability of a significant immunogenic
response. In addition to the main study, we would like to
assess extracellular secretion property of pET22b in the
Luria-Bertani (LB) medium.
2. Materials and methods
The E. coli cloning strains DH5a and BL21 (DE3)
were grown at 37C with aeration in the LB medium.
When appropriate, the LB medium was supplemented
with ampicillin (100 mg/mL) for plasmid selection. The
growth media for these bacteria were purchased from
Himedia Company, Mumbai - India. A plasmid encoding
the C-terminally 6xHis-tagged recombinant protein
LysK-CHAP in a pEX backbone (MWG-Biotech,
Ebersberg, Germany)was constructed. Overexpression of
proteins was performed in E. coli BL21 (DE3) (Invi-
trogen, Carlsbad, CA, USA) cultured at 37C in modified
LBmedium (15 g/L tryptone, 8 g/L yeast extract, and 5 g/
L NaCl) [36] supplemented with 100 mg/mL ampicillin
for plasmid selection and maintenance. Vectors, pEX and
pET22b, containing LysK-CHAP sequences were diges-
ted with NcoI and HindIII restriction enzymes, and then
the sticky vectors were ligated by T4 ligase enzyme.
Cloning was confirmed by double digestion. Cloning
accuracy was confirmed by electrophoresis.
2.1. Protein expression
The pET22b-LysK-CHAP plasmid was used to
transform the E. coli strain BL21, which allows IPTG-
regulated expression of T7 RNA polymerase. For
258 H.H. Kashani, R. Moniriconfirming the expression, 5 mL cultures were grown in
an air shaker (250 rpm) at 37C in the LB medium
containing 100 mg/mL of ampicillin. At OD600 Z 0.5,
IPTG was added to a final concentration of 1mM to
induce the T7 RNA polymerase-based expression. IPTG
induction was done at a lower temperature (30C),
which has been shown to enhance LysK protein
expression. Finally, western blot confirmed the expres-
sion of target protein.3. Results
In the current study, cloning was confirmed with
double digestion and analyzed with agarose gel; the
presence of an 809-bp band confirmed cloning of the
LysK gene (Figure 1).
Observation of a 28.5 kDa protein band confirmed
LysK-CHAP protein expression (Figure 2).
Although protein expression was confirmed in this
study, we could not detect any protein in the LB me-
dium. This means that most of the protein has been
secreted in the preplasmic area or inside of the bacterial
cell.4. Discussion
In the present study, LysK-CHAP domain was suc-
cessfully cloned and expressed at the pET22b vector and
E. coli BL21 (DE3). This kind of lysin was previously
studied by several scientists [15,19,20], but in our study
for assessment of extracellular secretion of protein of
LysK-CHAP domain, the domain was cloned in the
pET22b vector and transformed into E. coli BL21 (DE3)
for expression of the desired protein. According to our
mentioned data, protein was expressed by the vector but
should be scaled up for optimum production. In this
study no sign of protein was detected in the LB medium
but Cytoplasmic protein expression was confirmed by
SDS-PAGE and western blotting.Figure 1. Cloning confirmation of LysK in pET22-vector.To our knowledge, only a few phage endolysins,
such as LysK, phi11, MV-L, and LysH5, have been
reported to lyse live staphylococcal cultures [15,19,20].
LysK has a modular structure similar to the structure of
these endolysins, with two catalytic domains, a CHAP
domain and a central amidase-2 domain (N-ace-
tylmuramoyl-L-alanine amidase), as well as a C-ter-
minal SH3b cell-binding domain. In the current study,
we also synthesized the CHAP domain containing 165
amino acids. According to another study [37], this
sequence has a strong antibacterial potential. The po-
tential of these enzymes as novel therapeutics against a
number of Gram-positive pathogens on mucosal sur-
faces and in systemic infections has previously been
demonstrated [7e16]. In relation to bacterial resis-
tance, no strains with resistance to phage lysins have
yet been identified [1,3]. It has been suggested that
these enzymes have evolved to target specific mole-
cules in the host peptidoglycan that are essential for
cell viability, making resistance an unlikely event
[17,18]. In general, S. aureus phage lysins display a
multidomain modular structure comprising a C-termi-
nal cell wall binding domain and two N-terminal cat-
alytic domains. Examples include LysK, MV-L, phi11,
and LysH5 [5,15]. Native lysins of S. aureus, with the
exception of MV-L, have typically shown poor
expression, insolubility, and low activity when gener-
ated as recombinant proteins in a heterologous host [5].
However, their modular structure has enabled the
construction of truncated (CHAP) and chimeric ver-
sions of lysins (ClyS and P16-17) [16,22] to help
circumvent these problems. Scientists previously
showed that the activity of CHAPK against live S.
aureus including MRSA was twofold higher than that
of the native enzyme LysK [30]. To date, the multi-
domain MV-L lysin from phage MR11 and the
chimeric two-domain lysin ClyS are the only anti-
staphylococcal lysins that have been evaluated in vivo
[15,16]. In this study, LysK proteins containing only
the CHAP domain was expressed. Construction of a
single-domain protein for therapeutic purposes is
desirable, as well as facilitating protein production; this
may decrease the possibility of a significant immuno-
genic response. Unlike antibiotics, intact endolysins are
large proteins that are capable of stimulating a humoral
immune response, especially when they are used
intravenously. Most endolysins have a modular orga-
nization with a conserved N-terminal catalytic domain
and a more diverse C-terminal cell wall binding
domain [37,38]. However, several S. aureus phages
produce endolysins with two catalytic domains at their
N terminus, such as those from phages K, f11, and
fMR11. These lytic enzymes present a CHAP domain
followed by an amidase-2 domain (N-acetylmuramoyl-
L-alanine amidase), where the CHAP domain seems to
be most effective in inducing lysis [5,15,24]. The
LysK-CHAP domain provides a valuable functional
Figure 2. Analysis of LysK-CHAP protein expression with two methods. (A) LysK-CHAP protein expression was analyzed with
SDS-PAGE. (B) LysK-CHAP protein expression was analyzed with Western blot. C Z control; CHAP Z cysteine/histidine-
dependent amidohydrolase/peptidase; SDS-PAGE = sodium dodecyl sulphate-polyacrylamide gel electrophoresis; M Z protein
Marker; S Z protein sample.
Expression of LysK-CHAP domain in E. coli BL21 (DE3) 259unit for domain-swapping studies. It would be inter-
esting to investigate if a chimeric protein with the
LysK-CHAP domain and a different substrate-binding
domain would have an altered spectrum of inhibition,
since it has been demonstrated that the CHAP domain
alone has the same spectrum of inhibition in all the
strains tested. Environments such as hospitals and
nursing homes with a high number of MRSA infections
can benefit considerably from exploitation of the
CHAP domain of LysK.
In the current study, we synthesized LysK-CHAP
domain and cloned it to the pET22b as a preplasmic
secretion vector that enabling to express a lytic protein.
Expression of a lytic protein in the preplasmic area of
pET22b promises to be a suitable method for the pro-
duction of lytic proteins for further applications.Conflicts of interest
All authors declare no conflicts of interest.
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